X
ASCO 2019 – Kantar takes a first look at interim data from the Phase 3 TITAN trial
https://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/asco-2019-kantar-interim-data-phase-3-titan-trial/
kantar
Cancer market commentary: Roche’s Tecentriq muscles into NSCLC
Roche’s PD-L1 drug has generated impressive data in second line lung cancer
Cancer market commentary: 3 highlights from ESMO (Part 1)
Commentary on key cancer data from ESMO by Stephanie Hawthorne